Comparative Pharmacology
Head-to-head clinical analysis: OMONTYS PRESERVATIVE FREE versus RETACRIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMONTYS PRESERVATIVE FREE versus RETACRIT.
OMONTYS PRESERVATIVE FREE vs RETACRIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epoetin alfa-epbx is a recombinant human erythropoietin that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on erythroid progenitor cells, promoting their survival, proliferation, and differentiation.
RETACRIT (epoetin alfa-epbx) is a recombinant human erythropoietin that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on erythroid progenitor cells, promoting their survival, proliferation, and differentiation into mature red blood cells.
The recommended dose of OMONTYS (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH) is 1080 mg subcutaneously twice weekly via a proprietary infusion pump.
50-100 IU/kg intravenously or subcutaneously three times weekly; initial dose 50 IU/kg three times weekly, titrated to target hemoglobin 10-12 g/dL.
None Documented
None Documented
Terminal elimination half-life is approximately 24–30 hours in patients with chronic kidney disease on dialysis; longer half-life may occur in patients with residual renal function.
Terminal elimination half-life is ~2.5-4.5 hours following intravenous administration; shorter in children; prolonged in hepatic impairment.
Primarily renal: approximately 60% of the dose excreted unchanged in urine; biliary/fecal elimination is a minor route (<10%).
Primarily hepatic metabolism; ~10% excreted unchanged in urine, remainder via feces as metabolites.
Category C
Category C
Erythropoiesis-Stimulating Agent
Erythropoiesis-Stimulating Agent